Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin

Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2015, Pages 671-679

  Chen, Grace ^a   Zhang, Wencan ^a   Serenko, Michael ^a  

^a TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

Author keywords

bleeding; coagulation; drug drug interaction; pharmacokinetics; platelet; vortioxetine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; ARACHIDONIC ACID; COLLAGEN; VORTIOXETINE; WARFARIN; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD CLOTTING; CHAPPED LIPS; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR DEPRESSION; MULTIPLE DRUG DOSE; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; THROMBOCYTE AGGREGATION; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; ASPIRIN; BLOOD COAGULATION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; SULFIDES; WARFARIN; YOUNG ADULT;

EID: 84928890447     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.456     Document Type: Article

References (29)

1. de Abajo FJ, Garcia-Rodriguez LA,. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008; 65: 795-803.
2. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH,. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163: 59-64.
3. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2005; 22: 175-181.
4. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008; 17: 328-335.
5. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E,. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011; 183: 1835-1843.
6. Cochran KA, Cavallari LH, Shapiro NL, Bishop JR,. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011; 33: 433-438.
7. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J,. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009; 7: 1314-1321.
8. Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L,. Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009; 18: 412-416.
9. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B,. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000; 68: 435-442.
10. Andrade C, Sandarsh S, Chethan KB, Nagesh KS,. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010; 71: 1565-1575.
11. Tesseromatis C, Alevizou A,. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet. 2008; 33: 225-230.
12. Brintellix [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2013.
13. Summary of Product Characteristics: Brintellix, H. Lundbeck A/S 2013. http://www.ema.europa eu/docs/en-GB/document-library/EPAR-Product-Information/human/002717/WC500159449.pdf.
14. Areberg J, Sogaard B, Hojer AM,. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young subjects. Basic Clin Pharmacol Toxicol. 2012; 111: 198-205.
15. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L,. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012; 40: 1357-1364.
16. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54: 3206-3221.
17. Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets [abstract]. Int J Psychiatry Clin Pract. 2012; 16: 47. Abstract P-71.
18. Mork A, Pehrson A, Brennum L, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340: 666-675.
19. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
20. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE,. Antithrombotic therapy in atrial fibrillation. Chest. 2001; 119: 194S-206S.
21. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG,. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001; 119: 220S-227S.
22. Cairns JA, Theroux P, Lewis HD, Jr, Ezekowitz M, Meade TW,. Antithrombotic agents in coronary artery disease. Chest. 2001; 119: 228S-252S.
23. Shin J,. Clinical pharmacogenomics of warfarin and clopidogrel. J Pharm Pract. 2012; 25: 428-438.
24. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992; 5: 54-59.
25. Food and Drug Administration. Guidance for Industry. Drug interaction studies-study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
26. Yamaguchi T, Hidaka N, Suemaru K, Araki H,. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull. 2008; 31: 1371-1375.
27. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
28. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
29. European Medicines Agency. Brintellix-EMEA/H/C/002717 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002717/WC500159449.pdf.